Media: | ||
Mike Rulis | +45 4442 3573 | mike@novonordisk.com |
Ambre Morley (US) | +1 609 216 5240 | abmo@novonordisk.com |
Investors: | ||
Kasper Roseeuw Poulsen | +45 4442 4303 | krop@novonordisk.com |
Frank Daniel Mersebach | +45 4442 0604 | fdni@novonordisk.com |
Lars Borup Jacobsen | +45 3075 3479 | lbpj@novonordisk.com |
Jannick Lindegaard (US) | +1 609 786 4575 | jlis@novonordisk.com |
Company announcement No 6 / 2013
Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 33,900 employees in 75 countries, and markets its products in 190 countries.
distributed by |